Identification

Summary

Calcium glycerophosphate is an medication used to treat low levels of phosphate or calcium, as well as an ingredient in dental products to prevent dental caries.

Generic Name
Calcium glycerophosphate
DrugBank Accession Number
DB11264
Background

Calcium glycerophosphate is a Calcium salt of glycerophosphoric acid that forms a white, fine, slightly hygroscopic powder. The commercial product is a mixture of calcium beta-, and D-, and L -alpha-glycerophosphate. By FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings, and fillings. It is also present in dental or oral hygiene products due to its cariostatic effects. It is suggested that calcium glycerophosphate promotes plaque-pH buffering, elevation of plaque Calcium and phosphate levels and direct interaction with dental mineral 2.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 210.135
Monoisotopic: 209.9606158
Chemical Formula
C3H7CaO6P
Synonyms
  • 1,2,3-Propanetriol, mono(dihydrogen phosphate) calcium salt
  • 1,2,3-Propanetriol, mono(dihydrogen phosphate), calcium salt
  • Calcium beta-glycerophosphate
  • calcium β-glycerophosphate
  • β-glycerophosphoric acid calcium salt

Pharmacology

Indication

Calcium glycerophosphate is found in OTC dental products such as toothpastes for the prevention of dental caries. As OTC products these do not have an official indication.

In prescription products it is indicated as a Calcium or phosphate donor for replacement or supplementation in patients with insufficient Calcium or phosphate.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

It is thought that calcium glycerophosphate may act through a variety of mechanisms to produce an anti-caries effect 2. These include increasing acid-resistance of the enamel, increasing enamel mineralization, modifying plaque, acting as a pH-buffer in plaque, and elevating Calcium and phosphate levels.

When used as an electrolyte replacement, calcium glycerophosphate donates Calcium and inorganic phosphate. Calcium glycerophosphate is preferable to calcium phosphate due to its increased solubility. Compared to combination calcium gluconate and potassium phosphate, calcium glycerophosphate produces greater phosphate retention which allows for increased Calcium retention and ultimately greater incorporation of the ions into bone structure 1.

Mechanism of action

Calcium glycerophosphate in combination with sodium monofluorophosphate was found to reduce the acid solubility of enamel. This is thought to be due to increased uptake of fluoride in a non-alkali soluble form at the expense of a fraction remaining in the alkali-soluble form of calcium fluoride 2. It is also thought that calcium glycerophosphate enhances the remineralization effect of sodium monofluorophosphate leading to greater remineralization of enamel but the mechanism behind this is unknown.

Calcium glycerophosphate reduces the decrease in plaque pH produced by sucrose solutions 2. This may be due to the buffering action of donated phosphate which acts as an acceptor to three hydrogen ions to form biphosphate, dihydrogen phosphate, and finally phosphoric acid. As bisphosphate and dihydrogen phosphate are amphoteric, these molecules can act as buffers against both acids and bases.

Studies on plaque-modification by calcium glycerophosphate have been inconsistent 2. Redections in plaque weight and plaque area have been noted in separate studies but neither has been confirmed and no causative link has been established in regards to calcium glycerophosphate's anti-caries effect.

Calcium glycerophosphate donates Calcium and inorganic phosphate resulting in elevated levels of the ions in plaque 2. These ions are important components of the mineral structure of teeth. As such, their presence supports maintenance of healthy tooth structure and mineralization.

In electrolyte replacement calcium glycerophosphate again acts as a donor of Calcium and phosphate. See Calcium Phosphate for pharmacological descriptions of calcium and phosphate.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Alsimine W Vitamins A DCalcium glycerophosphate (13 mg / amp) + Cyanocobalamin (10 mcg / amp) + Dexpanthenol (5 mg / amp) + Dexpanthenol (400 unit / amp) + Ferrous gluconate (16 mg / amp) + Riboflavin 5'-phosphate sodium (2 mg / amp) + Nicotinamide (40 mg / amp) + Pyridoxine hydrochloride (3 mg / amp) + Thiamine hydrochloride (4.5 mg / amp) + Vitamin A (10000 unit / amp)Capsule; LiquidOralAlsi Cie Ltee1978-12-312003-05-21Canada flag
BetacolCalcium glycerophosphate (50 mg) + Betaine hydrochloride (61 mg) + Choline bitartrate (2.5 mg) + Potassium bicarbonate (41 mg)CapsuleOralTherapeutic Foods Co.1989-12-151996-09-09Canada flag
Calcium InjCalcium glycerophosphate (10 mg) + Calcium levulinate (15 mg)LiquidIntramuscular; Intravenous; SubcutaneousKripps Pharmacy Ltd.1981-12-31Not applicableCanada flag
Formula 2025 TabCalcium glycerophosphate (34 mg / tab) + Calcium glycerophosphate (51 mg / tab)TabletOralStandard Process Inc.Not applicableNot applicableCanada flag
Formula 2025 TabCalcium glycerophosphate (34 mg / tab) + Calcium glycerophosphate (51 mg / tab)TabletOralStandard Process Inc.Not applicableNot applicableCanada flag
Perioe lucky fresh - breath careCalcium glycerophosphate (.13 g/100g) + Sodium fluorophosphate (.76 g/100g)PasteDentalLg Household & Health Care Ltd.2010-04-28Not applicableUS flag
Perioe lucky fresh - cavity careCalcium glycerophosphate (0.13 g/100g) + Pyridoxine hydrochloride (0.03 g/100g) + Sodium fluorophosphate (0.76 g/100g)PasteDentalLg Household & Health Care Ltd.2010-04-26Not applicableUS flag
Somarexin and C 1000Calcium glycerophosphate (13 mg / amp) + Ascorbic acid (500 mg / amp) + Cyanocobalamin (10 mcg / amp) + Dexpanthenol (5 mg / amp) + Ferrous gluconate (16 mg / amp) + Riboflavin 5'-phosphate sodium (2 mg / amp) + Nicotinamide (40 mg / amp) + Pyridoxine hydrochloride (3 mg / amp) + Thiamine hydrochloride (4.5 mg / amp)Liquid; TabletOralLaboratoire Lalco Inc.1977-12-312008-07-29Canada flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as glycerophosphates. These are compounds containing a glycerol linked to a phosphate group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Glycerophospholipids
Sub Class
Glycerophosphates
Direct Parent
Glycerophosphates
Alternative Parents
Alkyl phosphates / Organic calcium salts / Primary alcohols / Organic oxides / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic acyclic compound / Alkyl phosphate / Hydrocarbon derivative / Organic calcium salt / Organic oxide / Organic oxygen compound / Organic phosphoric acid derivative / Organic salt / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
calcium salt (CHEBI:31336)
Affected organisms
Not Available

Chemical Identifiers

UNII
Y56W30YB7O
CAS number
27214-00-2
InChI Key
UHHRFSOMMCWGSO-UHFFFAOYSA-L
InChI
InChI=1S/C3H9O6P.Ca/c4-1-3(2-5)9-10(6,7)8;/h3-5H,1-2H2,(H2,6,7,8);/q;+2/p-2
IUPAC Name
calcium 2-(phosphonooxy)propane-1,3-diol
SMILES
[Ca++].OCC(CO)OP([O-])([O-])=O

References

General References
  1. Draper HH, Yuen DE, Whyte RK: Calcium glycerophosphate as a source of calcium and phosphorus in total parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1991 Mar-Apr;15(2):176-80. [Article]
  2. Lynch RJ: Calcium glycerophosphate and caries: a review of the literature. Int Dent J. 2004;54(5 Suppl 1):310-4. [Article]
KEGG Drug
D01488
KEGG Compound
C12935
PubChem Substance
347911170
ChemSpider
56554
RxNav
1909
ChEBI
31336
ChEMBL
CHEMBL3707206
Wikipedia
Calcium_glycerophosphate
MSDS
Download (46.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionDental Decay1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule; liquidOral
CapsuleOral
LiquidIntramuscular; Intravenous; Subcutaneous
TabletOral
LiquidOral
PasteDental
Liquid; tabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes at 170MSDS
water solubilitySolubleMSDS
Predicted Properties
PropertyValueSource
Water Solubility50.9 mg/mLALOGPS
logP-1ALOGPS
logP-2ChemAxon
logS-0.71ALOGPS
pKa (Strongest Acidic)1.13ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area112.88 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity29.15 m3·mol-1ChemAxon
Polarizability12.63 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 03, 2015 16:51 / Updated at September 28, 2021 21:54